{"id":5322,"date":"2020-12-14T00:00:00","date_gmt":"2020-12-14T00:00:00","guid":{"rendered":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/12\/14\/adding-baricitinib-speeds-recovery-for-covid-19-pneumonia\/"},"modified":"2020-12-15T18:10:22","modified_gmt":"2020-12-15T18:10:22","slug":"adding-baricitinib-speeds-recovery-for-covid-19-pneumonia","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/12\/14\/adding-baricitinib-speeds-recovery-for-covid-19-pneumonia\/","title":{"rendered":"Adding Baricitinib Speeds Recovery for COVID-19 Pneumonia"},"content":{"rendered":"<h3>\n<p>Odds of improvement in clinical status at day 15 greater for baricitinib plus remdesivir versus remdesivir alone<\/p>\n<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>MONDAY, Dec. 14, 2020 (HealthDay News) &#8212; For hospitalized adults with COVID-19, baricitinib plus remdesivir is better for reducing recovery time and improving clinical status than remdesivir alone, according to a study published online Dec. 11 in the <em>New England Journal of Medicine.<\/em><\/p>\n<p>Andre C. Kalil, M.D., M.P.H., from the University of Nebraska Medical Center in Omaha, and colleagues conducted a randomized, placebo-controlled trial examining baricitinib plus remdesivir in hospitalized adults with COVID-19. A total of 1,033 patients were randomly assigned: 515 were assigned to receive baricitinib plus remdesivir (combination treatment) and 518 to placebo plus remdesivir (control).<\/p>\n<p>The researchers found that the median time to recovery was seven and eight days for combination treatment versus control (rate ratio for recovery, 1.16; 95 percent confidence interval [CI], 1.01 to 1.32; P = 0.03). Patients receiving baricitinib had higher odds of improvement in clinical status at day 15 (odds ratio, 1.30; 95 percent CI, 1.0 to 1.6). For patients receiving high-flow oxygen or noninvasive ventilation at enrollment, the time to recovery was 10 and 18 days with combination treatment and control, respectively (rate ratio for recovery, 1.51; 95 percent CI, 1.10 to 2.08). The 28-day mortality was 5.1 and 7.8 percent in the combination and control groups, respectively (hazard ratio for death, 0.65; 95 percent CI, 0.39 to 1.09). Serious adverse events and new infections were less frequent in the combination versus control group.<\/p>\n<p>&#8220;Results of this study demonstrated baricitinib in combination with remdesivir provided a faster median recovery time and reduced progression to ventilation or death compared to remdesivir alone in hospitalized COVID-19 patients on oxygen,&#8221; Kalil said in a statement.<\/p>\n<p>Gilead Sciences provided remdesivir and Eli Lilly provided baricitinib for use in this trial but neither provided any financial support. <\/p>\n<p><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2031994\" target=\"_blank\" rel=\"noopener noreferrer\">Abstract\/Full Text<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2020 <a href=\"http:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Odds of improvement in clinical status at day 15 greater for baricitinib plus remdesivir versus remdesivir alone<\/p>\n","protected":false},"author":4,"featured_media":5515,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[85],"tags":[100,125],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/5322"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=5322"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/5322\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media\/5515"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=5322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=5322"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=5322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}